FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Pregnancy raises risks to mental health in MS patients, study says
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.
Report: Hawai‘i Prison Guards Face ‘Unsustainable’ Working Conditions
Staff vacancies require corrections officers to work at least 16- or 24-hour shifts, and the mandatory overtime takes a toll.
BioSpace1d
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
Chattanooga Times Free Press1d
TennCare’s maternal death rates are 3 times those of private insurance
Tennessee has long had one of the highest maternal death rates in the nation, but newly released data shows the risks of ...
FiercePharma1d
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
J&J wins label expansion for depression therapy Spravato
Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...